Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

NON-ALCOHOLIC STEATOHEPATITIS Clinical Trial

Official title:

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed Non-alcoholic Steatohepatitis (NASH)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06054815
• Other study ID #: DA1241_NASH_IIa
• Status: Recruiting
• Phase: Phase 2
• Start date: September 14, 2023
• Est. completion date: December 2024

Study information

• Verified date: June 2024
• Source: NeuroBo Pharmaceuticals Inc.
• Contact: Robert Homolka
• Phone: (917) 633-6086
• Email: CRInfo[@]neurobopharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA 1241 in subjects with presumed non-alcoholic steatohepatitis (NASH).

Description:

Clinical trial DA1241_NASH_IIa is a multicenter, randomized, double-blind, placebo-controlled, parallel-arm, Phase 2a clinical trial to evaluate the efficacy and safety of DA-1241 in subjects with presumed NAFLD.

Part 1 of this clinical trial intends to explore the efficacy of DA-1241 in subjects with NASH after administration of oral DA-1241 at varying doses or identical placebo in 3 treatment groups for 16 weeks/112 days.

Part 2 intends to explore the efficacy of DA-1241 in subjects with NASH after administration of oral DA-1241 in combination with sitagliptin versus an identical placebo for 16 weeks/112 days.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 87
• Est. completion date: December 2024
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria

1. Subjects who are able to understand and sign informed consent before the conduct of any protocol specific screening procedures.

2. Subjects who are male or female, aged 18 to 75 years inclusive at the time of consent.

3. Female subjects of childbearing potential:

1. Must agree to abide by contraception requirements, must not be lactating, and avoid pregnancy during study participation from the first Screening visit until 30 days after the last dose of study drug.

2. Must commit to an additional method of birth control in addition to male partners agreeing to use condoms with spermicide, throughout the study including for at least 30 days after the last dose of the study drug:

• True abstinence: Refraining from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the subject (periodic abstinence [eg, calendar, ovulation, symptothermal, post ovulation methods] and withdrawal are not acceptable).

• Combined (containing estrogen and progestogen) hormonal birth control (oral, intravaginal, injectable, or transdermal) associated with inhibition of ovulation initiated at least 30 days before dose administration.

• Progestogen only hormonal birth control (oral, injectable, or implantable) associated with inhibition of ovulation initiated at least 30 days before study dose administration.

• Bilateral tubal occlusion/ligation.

• Intrauterine device (IUD).

• Intrauterine hormone releasing system (IUS).

• Vasectomized partner.

4. Female subjects of non-childbearing potential do not need to use birth control during or after study drug treatment if considered of non-childbearing potential due to any of the following criteria:

1. Premenopausal female with permanent sterility or permanent infertility as due to one of the following:

• Permanent sterility due to a hysterectomy, bilateral salpingectomy, bilateral oophorectomy.

• Non-surgical permanent infertility due to Mullerian agenesis, androgen insensitivity, or gonadal dysgenesis; Investigator discretion should be applied to determining study entry for these individuals.

2. Postmenopausal female subjects, with no menses for 12 or more months without an alternative medical cause AND a follicle stimulating hormone (FSH) level = 40 IU/L.

5. Male subjects who are sexually active with a female partner of childbearing potential must agree to use male condoms and spermicide, even if the male subject has undergone a successful vasectomy (males with vasectomy can use condoms without spermicide), from Day 1 until at least 30 days after the last dose of the study drug.

6. Subjects with a BMI > 23 kg/m2 at first Screening Period visit.

7. Subjects with a qualifying ALT result (40 IU/L = ALT < 200 IU/L) as determined by the laboratory assessment at the first Screening Period visit.

8. Subjects with a confirmed NASH diagnosis or conditions consistent with NASH.

9. Subjects with an HbA1c = 5.7% and < 9.5% (5.7% = HbA1c < 9.5%).

10. Subjects with = 8% hepatic fat on MRI after confirming a qualifying ALT result at Screening.

11. Subjects with CAP score by FibroScan® of = 290 dB/m at the time of the first Screening Period visit.

12. Subjects with 7 kPa = VCTE score by FibroScan® < 14 kPa at the time of the first Screening Period visit.

13. For subjects receiving stable doses of the following medications prior to the first Screening Period visit, the following conditions applied:

1. Sodium-glucose cotransporter-2 (SGLT-2): no dose changes for at least 12 weeks prior to the first Screening Period visit.

2. Insulin and oral antidiabetic medications or drugs for dyslipidemia: no dose changes for at least 8 weeks prior to the first Screening Period visit; defined as a change of no more than a ± 25% in total daily dose of insulin during this period.

3. Vitamin E > 400 I/U: daily dose of = 800 I/U, stable for at least 12 weeks prior to the first Screening Period visit.

4. HMG-CoA Reductase Inhibitor (statins): no dose changes for at least 8 weeks prior to the first Screening Period visit.

Exclusion Criteria

1. Subjects who have used an investigational agent within 30 days or 5 elimination half-lives; whichever is longer prior to the first Screening Period visit.

2. Subjects diagnosed with liver disease other than NASH (eg, chronic viral hepatitis, decompensated cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, a-1-antitrypsin deficiency, primary biliary cholangitis, drug-induced liver disease).

3. Subjects who have a positive test result for hepatitis A virus immunoglobulin M, hepatitis B surface antigen, hepatitis B core antibody, hepatitis C virus antibody, or reactive human immunodeficiency virus (HIV) after providing a qualifying ALT result at the first Screening Period visit, or who have a known history of HIV infection. However, subjects with a positive hepatitis C virus antibody could be eligible after undergoing reflex testing (HCV-RNA negative) and evaluation by the Investigator.

4. Clinically significant laboratory results as evaluated by the Investigator after providing a qualifying ALT result at the first Screening Period visit. Subjects will be excluded if:

1. AST = 200 U/L

2. Platelets = 150,000/mm3

3. Albumin < 3.8 g/dL

4. Total bilirubin = 1.5 mg/dl, except with clinical diagnosis of Gilbert's syndrome

5. Direct bilirubin > 0.3 mg/dL

6. Phosphatidylethanol > 40 ng/mL

7. INR > 1.3 in the absence of anticoagulants

5. Subjects with an estimated glomerular filtration rate < 60 mL/min/1.73m2 based on modification of Diet in Renal Disease (MDRD) formula.

6. Subjects with a corrected QT interval by Fridericia (QTcF) of > 450 ms in males, and > 470 ms in females.

7. Subjects who are taking one or more of the following medications:

1. Within 12 weeks prior to the first Screening Period visit: i. Medication that is known to cause or worsen fatty liver disease (amiodarone, valproate, tamoxifen, methotrexate, etc.) for > 14 days. ii. Medication for weight loss. iii. Chronic use of systemic corticosteroids for > 14 days; however, administration of intranasal, topical, or inhaled corticosteroids is allowed. iv. DPP-4 inhibitors, thiazolidinediones (TZDs), or GLP-1 agonists.

2. St. John's Wort or consuming grapefruit juice within 2 weeks prior to the first Screening Period visit.

3. Digoxin, strong CYP3A4 inhibitors (a = 10-fold increase in AUC of sensitive substrate), or strong CYP3A4 inducers (decreases the AUC of sensitive index substrates of a given metabolic pathway = 80% increase) received within 5 half-lives or 14 days (whichever is longer) prior to the first Screening Period visit.

8. Subjects who cannot get an MRI scan.

9. Subjects who have a history of cirrhosis, a VCTE = 14 kPa, portal hypertension as evidenced by a history of splenomegaly > 15 cm, ascites, hepatic encephalopathy, varices on imaging/endoscopy or history of variceal bleeding, or a Model for End Stage Liver Disease (MELD) score > 10.

10. Subjects who have undergone bariatric surgery within 5 years prior to the first Screening Period visit after confirming a qualifying ALT result or are planning bariatric surgery during the clinical trial.

11. Subjects with a history of malignancy within 2 years prior to the first Screening Period visit. However, subjects who have completed all cancer therapies with no evidence of active malignancy within the 2 years prior to the first Screening Period visit will be allowed, except for squamous cell or basal cell carcinoma of the skin definitively treated > 12 weeks prior to the first Screening Period visit.

12. Subjects who have a presence of clinically significant cardiac (including Grade III/IV heart failure as defined by the New York Heart Association Criteria [Appendix 10.2]). This includes subjects with a history of myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft, or stroke within 90 days prior to the first Screening Period visit.

13. Subjects with a history of acute cardiovascular disease (uncontrolled arrhythmia, unstable angina, myocardial infarction, stroke, transient ischemic attack, cerebrovascular disease, etc.) within 12 weeks prior to the first Screening Period visit.

14. Subjects with a history of drug abuse or alcohol addiction within 12 weeks prior to the first Screening Period visit.

15. Subjects with a positive screen for drugs of abuse (ie, amphetamines, barbiturates, benzodiazepines, cocaine, methadone, opiate metabolite, and phencyclidine). Subjects who have been prescribed benzodiazepine or opiates for stable chronic medical illness may still qualify for the study at the discretion of the Investigator and review of the Medical Monitor.

16. Subjects who have physical (severe disorders in liver, heart, kidney, lung, blood, endocrine system, musculoskeletal system, gastrointestinal system, etc.) or mental (cognitive impairment, mental illness) conditions that may affect the subject's ability to participate in the clinical trial.

17. If female, subjects who are pregnant or lactating or intend to become pregnant during the clinical trial.

18. If male, subjects who intend to impregnate a partner.

19. Subjects who intend to donate ova or sperm during the clinical trial.

20. Subjects with known or suspected intolerance or hypersensitivity to IPs, closely-related compounds, or any of the stated ingredients.

21. Subjects with a weight change of > 10% measured at the first Screening Period and TP1 visits.

22. Subjects who cannot communicate reliably with the Investigator or are unlikely to cooperate with the requirements of the clinical trial.

23. Subjects with any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment or could interfere with the subject's participation in, or completion of, the clinical trial.

Related Conditions & MeSH terms

• Fatty Liver
• Non-alcoholic Fatty Liver Disease
• NON-ALCOHOLIC STEATOHEPATITIS

Intervention

Drug:
• DA-1241
Route of Administration: Oral, with subjects in a fasting state
• Sitagliptin
Route of Administration: Oral, with subjects in a fasting state
• DA-1241 Placebo
Route of Administration: Oral, with subjects in a fasting state
• Sitagliptin Placebo
Route of Administration: Oral, with subjects in a fasting state

Locations

Country	Name	City	State
United States	Excel Medical Trials	Boca Raton	Florida
United States	Southern California Research Center	Coronado	California
United States	Integrity Clinical Research, LLC	Doral	Florida
United States	South Texas Research Institute - A Pinnacle Entity	Edinburg	Texas
United States	Dallas Research Institute, LLC	Farmers Branch	Texas
United States	AIG Digestive Disease Research	Florham Park	New Jersey
United States	GI Associates & Endoscopy Center	Flowood	Mississippi
United States	Pinnacle Clinical Research - Georgetown	Georgetown	Texas
United States	Pioneer Research Solutions Inc.	Houston	Texas
United States	Lake Center for Clinical Research	Lady Lake	Florida
United States	Tandem Clinical Research GI, LLC	Marrero	Louisiana
United States	Clinical Pharmacology of Miami, LLC	Miami	Florida
United States	Suncoast Research Group, LLC	Miami	Florida
United States	Floridian Clinical Research	Miami Lakes	Florida
United States	Catalina Research Institute, LLC	Montclair	California
United States	Tandem Clinical Research GI, LLC	New York	New York
United States	Sensible Healthcare, LLC	Ocoee	Florida
United States	Velocity Clinical Research, Panorama City	Panorama City	California
United States	Inland Empire Clinical Trials, LLC	Rialto	California
United States	American Research Corporation	San Antonio	Texas
United States	Apex Mobile Clinical Research, LLC	San Antonio	Texas
United States	Pinnacle Clinical Research - San Antonio	San Antonio	Texas
United States	Texas Digestive Disease Consultants - San Marcos	San Marcos	Texas
United States	Liver Institute Northwest	Seattle	Washington
United States	Kansas Medical Clinical, PA	Topeka	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
NeuroBo Pharmaceuticals Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change alanine transaminase (ALT) levels	To explore the efficacy (change from baseline in alanine transaminase [ALT]) of DA-1241 in subjects at risk of NASH or subjects with non-alcoholic fatty liver disease (NAFLD) after administration of oral DA-1241 at varying doses of placebo and in combination with sitagliptin.	Baseline to Day 112
Secondary	ALT Normalization	Proportion of subjects with normalization of ALT: < 30 IU/L	Baseline to Day 112
Secondary	AST, GGT, ALP	Absolute change in aspartate transaminase (AST), gamma glutamyl transpeptidase (GGT), and alkaline phosphatase (ALP).	Baseline to Day 112
Secondary	Total cholesterol, LDL, HDL, triglyceride, and free fatty acids	Absolute change in total cholesterol, low and high-density lipoprotein cholesterol, triglyceride, and free fatty acids from baseline.	Baseline to Day 112
Secondary	A1c	Absolute change in hemoglobin A1c (HbA1c) (%).	Baseline to Day 112
Secondary	Glucose	Absolute change in fasting plasma glucose (mg/dL).	Baseline to Day 112
Secondary	Fasting insulin	Absolute change in fasting insulin.	Baseline to Day 112
Secondary	HOMA-IR	Absolute change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR).	Baseline to Day 112
Secondary	Adipo-IR	Absolute change in adipose tissue insulin resistance index (adipo-IR).	Baseline to Day 112
Secondary	CAP	Absolute change in controlled attenuation parameter (CAP) score assessed by FibroScan®.	Baseline to Day 112
Secondary	VCTE	Absolute change in vibration-controlled transient elastography (VCTE) score assessed by FibroScan®.	Baseline to Day 112
Secondary	FAST	Absolute change in FibroScan®- AST (FAST) score.	Baseline to Day 112
Secondary	Body weight	Absolute change in body weight.	Baseline to Day 112